EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL SANDOZ 600 mg/200 mg/245 mg, film-coated tablet 30 tablets
Active ingredients: Emtricitabine, Tenofovir disoproxil succinate, Tenofovir disoproxil, Efavirenz
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL SANDOZ 600 mg/200 mg/245 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 30 comprimé(s)
- Marketing authorisation holder
- SANDOZ
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 8 Aug 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61814540CIP73011757CIP133400930117576Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ÉFAVIRENZcomprimé | 600 mg · un comprimé | SA |
| TÉNOFOVIR DISOPROXILcomprimé | 245 mg · un comprimé | FT |
| SUCCINATE DE TÉNOFOVIR DISOPROXILcomprimé | 300,6 mg · uncomprimé | SA |
| EMTRICITABINEcomprimé | 200 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.